**Supplementary Table 3. Predictive factors for better BCVA change from baseline to Month 6 (multivariate analyses).**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | **BCVA change since inclusion injection to Month 6** | | | |
|  | β | SE | [95% CI] | p-value |
| **BRVO, n=105\*** |  |  |  |  |
| Age at baseline, years |  |  |  | 0.0270 |
| 18-59 | ref |  |  |  |
| 60-69 | 0.4 | 3.1 | [-5.8; 6.5] |  |
| 70-79 | -3.2 | 3.2 | [-9.5; 3.2] |  |
| ≥80 | -8.5 | 3.5 | [15.4; -1.6] |  |
| BCVA at baseline, ETDRS letters |  |  |  | <0.0001 |
| < 59 | ref |  |  |  |
| 59-70 | -12.2 | 2.8 | [-17.8; -6.6] |  |
| ≥ 70 | -13.7 | 2.9 | [-19.5; -7.8] |  |
| Absolute BCVA change since inclusion injection to Month 3, ETDRS letters |  |  |  | 0.0018 |
| ≤ -5 | Ref |  |  |  |
| 5-14 | 3.9 | 3.3 | [-2.8; 10.5] |  |
| ≥ 15 | 10.7 | 3.1 | [4.6; 16.8] |  |
|  |  |  |  |  |
| **CRVO, n=95\*** |  |  |  |  |
| Age at baseline, years |  |  |  | 0.0012 |
| 18-59 | ref |  |  |  |
| 60-69 | -12.1 | 6.1 | [-24.3; 0.1] |  |
| 70-79 | -22.7 | 6.1 | [-34.8; -10.6] |  |
| ≥80 | -21.0 | 5.9 | [-32.8; -9.3] |  |
| BCVA at baseline, ETDRS letters |  |  |  | 0.0244 |
| < 20 | ref |  |  |  |
| 20-59 | -9.7 | 5.4 | [-20.4; 1.0] |  |
| ≥ 59 | -16.9 | 6.1 | [-28.9; -4.8] |  |
| Absolute BCVA change since inclusion injection to Month 3, by class |  |  |  |  |
| ≤ -5 | -22.4 | 8.6 | [-39.5; -5.3] | <0.0001 |
| -4-4 | ref |  |  |  |
| 5-14 | -0.3 | 7.5 | [-15.3; 14.7] |  |
| ≥ 15 | 19.5 | 5.8 | [7.9; 31.1] |  |

\*Multivariate models included patients with no missing data for the variables selected from univariate analysis.

The multivariate linear regression model included explanatory variables that had a positive association with better BCVA change from baseline to Month 6 or Month 24 in univariate analyses. BCVA=best corrected visual acuity, BRVO=branch retinal vein occlusion, CRT=central retinal thickness, CRVO=central retinal vein occlusion